Advanced Enzyme Technologies Ltd Stock Price Today (NSE: ADVENZYMES)
Fundamental Score
Advanced Enzyme Technologies Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Advanced Enzyme Technologies Ltd share price today is ₹372.80, up +1.15% on NSE/BSE as of 17 June 2026. Advanced Enzyme Technologies Ltd (ADVENZYMES) is a Small-cap company in the Biotechnology sector with a market capitalisation of ₹3.49K (Cr). The 52-week high for ADVENZYMES share price is ₹419.00 and the 52-week low is ₹251.95. At a P/E ratio of 23.70x, ADVENZYMES is currently trading below its industry average P/E of 51.82x. The company has a Return on Equity (ROE) of 9.54% and a debt-to-equity ratio of 0.02.
Advanced Enzyme Technologies Ltd Share Price Chart — NSE/BSE Historical Performance
Advanced Enzyme Technologies Ltd share price chart: 13.23% return over the past month. 52-week high ₹419.00, 52-week low ₹251.95.
Advanced Enzyme Technologies Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹378.85 | ₹395.00 | ₹365.00 | ₹392.10 | 3.70L (Cr) | |
| ₹369.45 | ₹383.00 | ₹360.60 | ₹379.55 | 4.25L (Cr) | |
| ₹371.75 | ₹371.75 | ₹362.50 | ₹364.00 | 1.33L (Cr) | |
| ₹378.00 | ₹378.25 | ₹364.60 | ₹371.75 | 1.78L (Cr) | |
| ₹377.00 | ₹384.60 | ₹375.00 | ₹376.80 | 1.25L (Cr) | |
| ₹380.90 | ₹387.60 | ₹375.30 | ₹376.85 | 1.35L (Cr) | |
| ₹389.85 | ₹390.00 | ₹371.35 | ₹375.15 | 1.38L (Cr) | |
| ₹393.70 | ₹393.70 | ₹380.15 | ₹386.20 | 1.76L (Cr) | |
| ₹380.10 | ₹394.95 | ₹377.70 | ₹388.90 | 2.86L (Cr) | |
| ₹363.50 | ₹389.90 | ₹359.00 | ₹386.30 | 5.35L (Cr) |
Advanced Enzyme Technologies Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹369.45 | ₹395.00 | ₹360.60 | ₹392.10 | +6.13% | |
| ₹350.00 | ₹419.00 | ₹347.50 | ₹364.00 | +4.00% | |
| ₹268.90 | ₹350.95 | ₹260.00 | ₹347.70 | +29.30% | |
| ₹290.10 | ₹303.90 | ₹251.95 | ₹255.30 | -12.00% | |
| ₹273.00 | ₹319.20 | ₹259.00 | ₹300.30 | +10.00% | |
| ₹303.35 | ₹315.15 | ₹262.20 | ₹296.80 | -2.16% | |
| ₹311.00 | ₹318.95 | ₹286.35 | ₹302.25 | -2.81% | |
| ₹308.05 | ₹353.30 | ₹304.30 | ₹311.70 | +1.18% | |
| ₹327.00 | ₹334.45 | ₹299.00 | ₹308.05 | -5.80% | |
| ₹344.95 | ₹359.60 | ₹317.10 | ₹325.70 | -5.58% | |
| ₹352.00 | ₹366.25 | ₹292.25 | ₹345.95 | -1.72% | |
| ₹322.45 | ₹359.90 | ₹318.60 | ₹350.70 | +8.76% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Small-cap play on India's biotech ambitions; size accordingly, watch closely.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Change in management announced on April 9, 2026. The company also announced the closure of the trading window effective April 1, 2026.
CORE STORY (THE REAL GAME)
Advanced Enzyme is a bet on the long-term growth of the Indian biotech and biomanufacturing sector, fueled by the BioE3 policy. It's not a quarter-to-quarter earnings play; it's about riding the wave of increasing adoption of enzymes in various industries.
- FII interest increasing
- Sector tailwinds from BioE3 policy
- Government support for biotech
- Significant order wins in biomanufacturing
- Successful integration of any future acquisitions
- Faster-than-expected growth in enzyme adoption
- Small-cap liquidity risk
- Weak sales and profit growth
- Returns on capital are concerning
FII increased holdings by 1.96%, DII decreased holdings by 2.04%, Promoter decreased holdings by 0.01%.
India's BioE3 policy aims to build a $300 billion biomanufacturing industry by 2030.
Free Cash Flow 5Y: ₹543.85 Cr, profit is converting to cash.
3-6 month thesis hinges on the company demonstrating improved execution and capitalizing on sector growth. Watch for order wins and margin expansion.
Primary Thesis Risk
Failure to execute on the India biotech growth story.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Advanced Enzyme Technologies Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Advanced Enzyme Technologies Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ADVENZYMES across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Operating Margins (35.13%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 23.70 vs Industry: 51.82)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (31.98%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (26.30%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (66.30x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹543.85 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 31.82%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Below-Average Return on Equity (9.54%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Weak Earnings Growth (0.22% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (0.26% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Advanced Enzyme Technologies Ltd vs Biotechnology Peers
Peer Comparison - Biotechnology
Compare Advanced Enzyme Technologies Ltd with 4 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Advanced Enzyme Technologies LtdAdvanced Enzyme...Selected✓ ADVENZYMES • 540025 | 63.6/100 | ₹372.80₹373 | ₹3493.23₹3493.23 | 23.70Average 23.7 Average | 9.54%Poor 9.54% Poor | 13.11%Average 13.11% Average | 0.02Excellent 0.0 Excellent | 0.26%Average 0.26% Average | 7.48%Good 7.48% Good | 1.66% |
Anthem Biosciences LimitedAnthem Bioscien... ANTHEM • 544449 | 63.7/100 | ₹757.20₹757 | ₹37009.24₹37009.24 | 79.93Average 79.9 Average | 20.83%Excellent 20.83% Excellent | 28.50%Excellent 28.50% Excellent | 0.04Excellent 0.0 Excellent | 37.27%Excellent 37.27% Excellent | 23.86%Excellent 23.86% Excellent | 0.00% |
Genesis IBRC India LtdGenesis IBRC In... GENESIS • 514336 | 25/100 | ₹116.90₹117 | ₹177.38₹177.38 | — — | 51.62%Excellent 51.62% Excellent | 51.62%Excellent 51.62% Excellent | 0.00Excellent 0.0 Excellent | 105.89%Excellent 105.89% Excellent | — — | 0.00% |
Vivo Bio Tech LtdVivo Bio Tech L... VIVOBIOT • 511509 | 16/100 | ₹27.08₹27 | ₹68.05₹68.05 | 16.64Average 16.6 Average | 5.68%Poor 5.68% Poor | 9.04%Poor 9.04% Poor | 0.58Good 0.6 Good | -3.27%Poor -3.27% Poor | -3.35%Poor -3.35% Poor | 0.00% |
Genomic Valley Biotech LtdGenomic Valley ... GVBL • 539206 | 24.6/100 | ₹26.54₹27 | ₹8.81₹8.81 | 88.14Average 88.1 Average | 9.68%Poor 9.68% Poor | 11.83%Average 11.83% Average | 0.00Excellent 0.0 Excellent | 4.42%Average 4.42% Average | -0.24%Poor -0.24% Poor | 0.00% |
Top Biotechnology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Anthem Biosciences Limited share price37009.24 Cr
- Genesis IBRC India Ltd share price177.38 Cr
- Vivo Bio Tech Ltd share price68.05 Cr
- Genomic Valley Biotech Ltd share price8.81 Cr
Advanced Enzyme Technologies Ltd PE Ratio History
Historical price-to-earnings ratio for ADVENZYMES — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹11.71 | ₹302.25 | 25.8x |
| FY 2024 | ₹11.92 | ₹348.35 | 29.2x |
| FY 2023 | ₹9.45 | ₹375.35 | 39.7x |
| FY 2022 | ₹10.68 | ₹280.80 | 26.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Advanced Enzyme Technologies Ltd Dividend History
Annual cash dividends paid by ADVENZYMES — dividend yield 1.66%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹59.03 Cr |
| FY 2024 | ₹56.71 Cr |
| FY 2023 | ₹12.54 Cr |
| FY 2022 | ₹11.86 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Advanced Enzyme Technologies Ltd Quarterly Performance
Latest quarterly metrics for ADVENZYMES — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
26.30%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
31.98%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
7.48%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
0.26%
Compounded annual net profit growth over 5 years
Advanced Enzyme Technologies Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ADVENZYMES — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Advanced Enzyme Technologies Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Advanced Enzyme Technologies Ltd (ADVENZYMES) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Advanced Enzyme Technologies Ltd
About ADVENZYMES (Advanced Enzyme Technologies Ltd)
Advanced Enzyme Technologies Ltd is a pioneering force in the realm of biotechnology, dedicated to harnessing the potent power of enzymes and probiotics. This innovative company me...ticulously researches, develops, and manufactures a comprehensive portfolio of biological catalysts and beneficial microorganisms, distributed across India, the US, Europe, Asia, and beyond. With a commitment to cutting-edge science and sustainable practices, ADVENZYMES formulates solutions designed to optimize various industrial processes and promote overall well-being. Its advanced product offerings stem from diligent scientific inquiry and rigorous quality control, ensuring efficacy and safety for a diverse range of applications, all rooted in the transformative potential of biocatalysis and microbial communities. ADVENZYMES caters to a diverse array of sectors, leveraging its enzyme and probiotic expertise to revolutionize processes within human healthcare and nutrition, animal feed enhancement, and diverse food processing applications. In human nutrition, the company provides targeted enzyme and probiotic supplements that promote digestive health and nutrient absorption. Furthermore, ADVENZYMES offers specialized solutions to enhance the efficiency of fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, and dairy production. Their product applications underscore a steadfast commitment to optimizing efficiency, improving product quality, and reducing environmental impact across a multitude of industries. Through strategic partnerships and a global distribution network, ADVENZYMES delivers its innovative enzyme and probiotic formulations to customers worldwide. The company's commitment to research and development fuels a continuous stream of innovative products designed to meet the ever-evolving needs of its clients. Emphasizing sustainable practices, ADVENZYMES seeks to promote responsible manufacturing processes and reduce its environmental footprint, reinforcing its position as a leader in the advancement of biotechnological solutions. The company remains dedicated to pushing the boundaries of enzyme and probiotic technology, delivering transformative benefits to industries and consumers on a global scale.
Company Details
Key Leadership
Corporate Events
ADVENZYMES Share Price: Frequently Asked Questions
What is the current share price of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd (ADVENZYMES) trades at ₹372.80 on NSE and BSE. Market cap ₹3.49K (Cr). Educational data only.
What is the P/E ratio of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd has a P/E of 23.70x vs industry average 51.82x.
What is the Bull Run score for Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd has a Bull Run score of 63.6/100 based on 25+ financial parameters.
Does Advanced Enzyme Technologies Ltd pay dividends?
Advanced Enzyme Technologies Ltd has a dividend yield of 1.66%. Past dividends don't guarantee future payments.
What is the ROE of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd has ROE of 9.54%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd has debt-to-equity of 0.02.
Is Advanced Enzyme Technologies Ltd a good investment?
Bull Run gives Advanced Enzyme Technologies Ltd a score of 63.6/100. This is not investment advice — consult a SEBI-registered advisor.